Phase 4 N=26 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face
Acne Vulgaris
Primary: Comparative Assessment of Facial Irritation and Cutaneous Effects. — 1.1; 2.7; 3.2; 6.2 Scores on a Scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=107 Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule
Hepatitis A
Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 748.1; 378.6; 419.3; 342.2 mIU/mL
Phase 4 N=78 Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule
Hepatitis A
Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 593.6; 297.4; 363.2; 287.7 mIU/mL
Phase 4 N=445 Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
Attention Deficit Hyperactivity Disorder
Primary: Mean Change in the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptom Score From Baseline to 12 Week Endpoint…
Phase 4 N=291 Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter
Atrial Flutter
Primary: Percentage of Subjects With Complete Bidirectional Conduction Block. — 93.3 percentage of participants — p=.05
Phase 4 N=200 An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline in PANSS Total Score at the End of the Double-blind Treatment Phase (Week 6 or the Last Assessment Obtained After the Baseline Assessment). — -11.7…
Phase 4 N=80 A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa
Infertility
Primary: Number of Participants With an Ongoing Pregnancy — 14; 13 participants
Phase 4 N=87 Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20 — 9.3; 8.2; -1.2 percentage change in HbA1c — p=<.0001
Phase 4 N=120 A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
Influenza
Primary: Number of Participants With at Least 1 Solicited Injection Site Solicited Systemic Reactions Post-vaccination With Fluzone® Vaccine. — 35; 18; 34; 16 Participants
Phase 4 N=628 A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma
Asthma
Primary: Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52 — 0.16; 0.12 Liters — p=0.090
Phase 4 N=1,570 Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza
Pain
Primary: Difference From Baseline (Week 0) in the Average Pain Score at Visit 3 (Week 6) — -1.6 units on scale
Phase 4 N=64 Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
Cataract
Primary: The Percentage of Patients With a Score of Zero for Anterior Chamber Cells. — 91.7 Percentage of participants
Phase 4 N=621 A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma
Asthma
Primary: Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52 — 0.20; 0.09 Liters — p=<0.001
Phase 4 N=181 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
Attention Deficit Hyperactivity Disorder · Oppositional Defiant Disorder
Primary: Swanson, Nolan and Pelham Rating Scale Revised (SNAP-IV) Oppositional Defiant Disorder: (ODD) Score — 8.6; 9.0; 12.0 units on a scale — p=<.001
Phase 4 N=54 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Comfort Immediately After Dosing — 7.8; 7.1 Units on a scale